GOSS
A tiny share count, now even tinier
Gossamer Bio just flipped the switch on a 1-for-80 reverse stock split. Translation: if you owned 80 shares, you now own 1 share worth 80 times as much. Same pie, fewer slices. Very glamorous on paper, slightly less glamorous in practice.
The company said it filed the necessary amendment with Delaware to make the split effective. That’s the administrative version of saying, “Yep, we’ve officially done the thing.”
Why investors should care
Reverse splits usually aren’t the kind of headline that makes bulls start doing cartwheels. They don’t magically create value, and they often show up when a stock has been under pressure and needs to get its price back into a more market-friendly range.
For Gossamer, the bigger story is still the underlying biotech grind: it’s a clinical-stage company leaning on seralutinib for pulmonary arterial hypertension and related lung disease. The split doesn’t change that pipeline, but it does tell you the company is managing its capital structure carefully while it keeps pushing the science.
Big picture
This is less “new growth story” and more “corporate housekeeping with consequences.” If you’re holding GOSS, the split changes the math on your share count, not the biology in the lab.